---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-000500"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:52:59.366148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech authorizes new $10M share repurchase program

## Summary
- Board authorized repurchase of up to $10M of common stock, effective immediately for two years.
- Prior program (June 2022) repurchased ~3.41M shares for ~$9.3M as of filing date.
- Program will be funded from available cash; CEO cites strong balance sheet and shareholder commitment.
- Company continues evaluating internal programs and exploring strategic opportunities.

## SEC filing metadata
- accession: 0001683168-23-000500
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/0001683168-23-000500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-000500
- JSON: https://secwatch.observer/filing/0001683168-23-000500.json
- Plain text: https://secwatch.observer/filing/0001683168-23-000500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.